Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-human cytomegalovirus monoclonal antibody combination CSJ-148

A combination agent composed of two human monoclonal antibodies against the human cytomegalovirus (HCMV), LJP538 and LJP539, with potential immunomodulating activity. Upon administration of CSJ-148, both LJP538 and LJP539 bind to and inhibit the function of viral HCMV glycoproteins that are essential for HCMV infection; LJP538 targets and binds to glycoprotein B (gB) and LJP539 targets and inhibits the pentameric complex, consisting of glycoproteins gH, gL, UL128, UL130, and UL131. Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:antiviral agent CSJ148
HCMV neutralizing human mAb combination CSJ-148
Code name:CSJ 148
CSJ-148
CSJ148
LJP538 and LJP539
LJP538 plus LJP539
LJP538/LJP539
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search